Zealand Pharma (ZLDPF) announces the implementation of long-term incentive programs for 2025 for Zealand Pharma’s Board of Directors, Corporate Management and employees in accordance with Zealand Pharma’s remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024. Zealand Pharma has made the following awards in its long-term incentive plan. It has awarded: 29,169 restricted share units to Zealand Pharma’s Board of Directors; 96,788 performance share units and 96,788 RSUs have been awarded to Zealand Pharma’s Corporate Management; 18,502 RSUs have been awarded to Zealand Pharma’s US employees and 128,519 RSU’s have been awarded to Zealand Pharma’s employees in Denmark.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
- Zealand Pharma completes enrollment in ZUPREME-1 trial
- Zealand Pharma upgraded to Buy from Hold at SEB Equities
- Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
- William Blair upgrades Zealand to Outperform on recent selloff